Patient-derived organoids predict chemotherapy response of locally advanced gastric cancer - PubMed

4 days ago

Patient-derived organoids (PDOs) were successfully generated from locally advanced gastric cancer (GC) patients with a 63% success rate.
PDOs accurately replicated the histopathological and genetic characteristics of the original tumors.
Drug sensitivity tests showed subtype-specific responses: signet-ring cell carcinoma (SRCC) PDOs were sensitive to epirubicin and paclitaxel but resistant to 5-fluorouracil (5-FU) and oxaliplatin.
Non-SRCC PDOs were sensitive to paclitaxel, epirubicin, and oxaliplatin, with paclitaxel being the most effective across both subtypes.
Ex vivo pharmacotyping of PDOs predicted clinical responses with 85.7% sensitivity, 100% specificity, and 90.9% accuracy.
Patients with drug-sensitive PDOs had significantly longer disease-free survival compared to those with drug-resistant PDOs (P = 0.044).
The study highlights PDOs as reliable preclinical models for predicting individualized treatment outcomes in GC.

Hasty Briefsbeta